Helix BioPharma Corp., a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers, announced today that its board of directors has granted 1,297,000 incentive stock options to directors, officers, employees and consultants under its equity compensation plan. Simultaneously, the company canceled 2,200,000 options previously granted to a director, a move that may signal a strategic realignment of executive incentives as the company advances its pipeline.
Each new option is exercisable at $1.63 per share for a period of five years, subject to vesting provisions outlined in the company's equity compensation plan. The canceled options, originally granted on July 19, 2024, had an exercise price of $1.10 per share and were set to expire in July 2029. Notably, the director who held the canceled options did not receive any new options in the current grant, according to the company's press release.
The grant and cancellation come as Helix BioPharma continues to develop its lead candidate, L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6-expressing tumors. The company has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and is leveraging the same targeting foundation for next-generation bi-specific antibody-drug conjugates (ADCs) in discovery. Additionally, Helix is advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug with bioavailability comparable to intravenous administration.
The stock option adjustments could be interpreted as a way to align management incentives with the company's near-term milestones, particularly as Helix seeks to move its pipeline toward later-stage clinical trials. The cancellation of a director's options at a lower strike price ($1.10) compared to the new grants ($1.63) may also reflect a recalibration of equity compensation to current market conditions.
For HR vendors serving the life sciences sector, this news underscores the importance of understanding how equity compensation strategies evolve during clinical development phases. Companies like Helix often use stock options to retain top talent and align interests with shareholders, but cancellations and re-grants can signal shifts in corporate priorities or governance changes. Vendors offering equity administration, compensation consulting, or executive incentive planning tools may find opportunities to support biotech firms navigating these complex decisions.
Helix BioPharma is listed on the TSX under the symbol HBP, on OTC PINK as HBPCD, and on the Frankfurt Stock Exchange as HBP0. More information about the company and its pipeline is available on its website at https://www.helixbiopharma.com/.
As with all forward-looking statements, the company cautions that actual results may differ materially from those expressed or implied, due to risks and uncertainties detailed in its filings on SEDAR+ at www.sedarplus.ca.
